Payment overview · 2025
General Payments
$217.17
11 reported records · 8 companies
Healthcare provider profile · identity verified
Amber Walker, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BOAZ, AL · NPI 1811448202
Verified facts
What the public records show
CMS Open Payments records show Amber Walker, CRNP received $217.17 in general payments during 2025 across 11 reported records.
Phathom Pharmaceuticals, Inc. accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.27 | 24.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.09 | 18.0% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $27.51 | 12.7% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $25.59 | 11.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $23.58 | 10.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.06 | 7.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.17 | 7.5% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $14.90 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $217.17 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $53.27 | 3 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $27.51 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 462 | 170 |
| Losartan Potassium | Losartan Potassium | 396 | 150 |
| Carvedilol | Carvedilol | 327 | 127 |
| Tramadol Hcl | Tramadol Hcl | 326 | 88 |
| Tizanidine Hcl | Tizanidine Hcl | 320 | 126 |
| Gabapentin | Gabapentin | 303 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 299 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 108 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 270 | 106 |
| Metformin Hcl | Metformin Hcl | 262 | 88 |
| Omeprazole | Omeprazole | 256 | 92 |
| Montelukast Sodium | Montelukast Sodium | 255 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 227 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 211 | 79 |
| Trazodone Hcl | Trazodone Hcl | 191 | 76 |
| Methylprednisolone | Methylprednisolone | 183 | 137 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 49 |
| Furosemide | Furosemide | 151 | 68 |
| Clonazepam | Clonazepam | 149 | 34 |
| Meloxicam | Meloxicam | 142 | 54 |
| Azithromycin | Azithromycin | 138 | 102 |
| Mounjaro | Tirzepatide | 135 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 130 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 48 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 116 | 82 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 42 |
| Buspirone Hcl | Buspirone Hcl | 103 | 34 |
| Lisinopril | Lisinopril | 103 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 40 |
| Levofloxacin | Levofloxacin | 92 | 71 |
| Ondansetron Odt | Ondansetron | 92 | 42 |
| Ozempic | Semaglutide | 90 | 24 |
| Simvastatin | Simvastatin | 89 | 31 |
| Potassium Chloride | Potassium Chloride | 88 | 29 |
| Eliquis | Apixaban | 85 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 32 |
| Trulicity | Dulaglutide | 81 | 21 |
| Topiramate | Topiramate | 77 | 30 |
| Jardiance | Empagliflozin | 76 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 27 |
| Alprazolam | Alprazolam | 66 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 40 |
| Prednisone | Prednisone | 63 | 36 |
| Clonidine Hcl | Clonidine Hcl | 60 | 20 |
| Methocarbamol | Methocarbamol | 60 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 21 |
| Warfarin Sodium | Warfarin Sodium | 59 | 12 |
| Mirtazapine | Mirtazapine | 57 | 17 |
| Famotidine | Famotidine | 55 | 26 |
| Ibuprofen | Ibuprofen | 54 | 18 |
| Spironolactone | Spironolactone | 54 | 18 |
| Glimepiride | Glimepiride | 53 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 22 |
| Fluconazole | Fluconazole | 52 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 45 |
| Mupirocin | Mupirocin | 49 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 15 |
| Sertraline Hcl | Sertraline Hcl | 47 | 18 |
| Meclizine Hcl | Meclizine Hcl | 44 | 25 |
| Pregabalin | Pregabalin | 44 | 12 |
| Telmisartan | Telmisartan | 44 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 41 | 12 |
| Nifedipine Er | Nifedipine | 41 | 15 |
| Farxiga | Dapagliflozin Propanediol | 40 | 15 |
| Lorazepam | Lorazepam | 40 | 14 |
| Donepezil Hcl | Donepezil Hcl | 39 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 13 |
| Fenofibrate | Fenofibrate | 37 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Atenolol | Atenolol | 36 | 11 |
| Allopurinol | Allopurinol | 35 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 13 |
| Nystatin | Nystatin | 35 | 18 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 35 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 17 |
| Vascepa | Icosapent Ethyl | 33 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 12 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 12 |
| Sucralfate | Sucralfate | 26 | 17 |
| Cefuroxime | Cefuroxime Axetil | 25 | 22 |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | 11 |
| Amoxicillin | Amoxicillin | 22 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Linzess | Linaclotide | 22 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 17 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 16 | 13 |
| Temazepam | Temazepam | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $217.17 · 11 records | Phathom Pharmaceuticals, Inc. | DUPIXENT, ENTYVIO, General - Pain Management, IBSRELA, MAVYRET, UZEDY, VOQUEZNA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error